Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin

Atherosclerosis

Volumn 175, Issue 2, 2004, Pages 287-293

  Kajinami, Kouji ^a,b,c   Brousseau, Margaret E ^a,b   Ordovas, Jose M ^a,b   Schaefer, Ernst J ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

ATP binding cassette transporter; Cholesterol 7 hydroxylase; HMG CoA reductase inhibitor; LDL cholesterol; Pharmacogenetics

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; WILD TYPE;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PYRROLES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 3242736602     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.03.015     Document Type: Article

References (17)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. US Department of Health and Human Services Public Health Service National Institutes of Health National Heart, Lung, and Blood Institute (NIH Publication No. 02-5215) September 2002.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
3. Shepherd J., Blauw G.J., Murphy M.B., et al. on behalf of the PROSPER study group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 360:2002;1623-1630
4. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 348:2003;529-537
5. Evans W.E., McLeod H. Pharmacogenomics drug disposition, drug targets, and side effects. N. Engl. J. Med. 348:2003;538-549
6. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., Black D.M., Stein E.M., Corella D., et al. Apolipoprotein E genotype affects plasma lipid response to atrovastatin in a gender specific manner. Atherosclerosis. 158:2001;183-193
7. Moore J.H., Williams S.M. New strategies for identifying gene-gene interactions in hypertension. Ann. Med. 34:2002;88-95
8. Berge K.E., Tian H., Graf G.A., et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 290:2000;1771-1775
9. Lee M.H., Lu K., Hazard S., et al. Idenfitication of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet. 27:2001;79-83
10. Hubacek J.A., Berge K.E., Cohen J.C., Hobbs H.H. Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Hum. Mutat. 18:2001;359-360
11. Bhattacharyya A.K., Connor W.E., Lin D.S., McMurry M.M., Shulman R.S. Sluggish sitosterol turnover and hepatic failure to excrete sitosterol into bile cause expansion of body pool of sitosterol in patients with sitosterolemia and xanthomatosis. Arterioscler. Thromb. 11:1991;1287-1294
12. Yu L., Hammer R.E., Hawkins J.L., von Bergmann K., Lutjohann D., Cohen J.C., et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. U.S.A. 99:2002;16237-16242
13. Wang J., Freeman D.J., Grundy S.M., Levine D.M., Guerra R., Cohen J.C. Linkage between cholesterol 7a-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J. Clin. Invest. 101:1998;1283-1291
14. Pullinger C.R., Eng C., Salen G., et al. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110:2002;109-117
15. Kajinami K., Brousseau M.E., Nartsupha C., Ordovas J.M., Schaefer E.J. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res. 45:2004;653-656
16. Kajinami K, Takekoshi N, Brousseau ME, Ordovas JM, Schaefer EJ. Additive gene-gene interaction between CYP7A1 and APOE as genetic determinants of LDL cholesterol-lowering response to atorvastatin (abstract). J Am Coll Cardiol 2004; 43(Suppl A):505A.
17. Davidson M., McKenney J., Stein E., Schrott H.G., Fayyad R., Black D. Comparison of 1 year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 79:1997;1475-1481